MedTrace Logo

Study of CAD-1883 for Spinocerebellar Ataxia

NCT04301284 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-04-08

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled Phase 2 study evaluating oral administration of CAD-1883 in the treatment of adults with a genotypic diagnosis of Spinocerebellar Ataxia (SCA). This study offers the opportunity to understand the safety, tolerability, and efficacy of CAD-1883 in the SCA patient population.

Conditions

  • Spinocerebellar Ataxias
  • Spinocerebellar Ataxia Type 1
  • Spinocerebellar Ataxia Type 2
  • Spinocerebellar Ataxia Type 3
  • Spinocerebellar Ataxia Type 6
  • Spinocerebellar Ataxia Type 7
  • Spinocerebellar Ataxia Type 8
  • Spinocerebellar Ataxia Type 10
  • Spinocerebellar Ataxia Type 17
  • ARCA1 - Autosomal Recessive Cerebellar Ataxia Type 1

Interventions

DRUG

CAD-1883

150 mg filled capsules

DRUG

Placebos

capsules

Sponsors & Collaborators

  • Cadent Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2022-11-30
Completion
2022-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04301284 on ClinicalTrials.gov